The local medical landscape is excited with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor showing significant results in early trials for managing obesity. This therapy suggests a https://veriea.com/2026/06/10/retatrutide-australia-the-next-generation-in-weight-loss/